<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75703">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105844</url>
  </required_header>
  <id_info>
    <org_study_id>SWISS-AF</org_study_id>
    <nct_id>NCT02105844</nct_id>
  </id_info>
  <brief_title>Swiss Atrial Fibrillation Cohort Study</brief_title>
  <acronym>SWISS-AF</acronym>
  <official_title>Swiss Atrial Fibrillation Cohort Study - SWISS AF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Swiss-AF is a prospective observational, multicentric cohort study in Switzerland. Overall,
      2600 patients with documented atrial fibrillation aged &gt;65 years will be included and
      followed on a yearly basis.

      Yearly clinical examinations include a detailed questionnaire on personal characteristics, a
      resting electrocardiogram, neurocognitive function tests and questionnaires on disability
      and quality of life. Blood sampling and brain magnetic resonance imaging are scheduled at
      baseline and after 2 years of follow-up.

      The main study aims of this long term prospective study are to increase our knowledge on
      structural brain damage and its changes over time in patients with atrial fibrillation, to
      gain additional insights on the incidence and underlying mechanisms of cognitive decline in
      patients with atrial fibrillation and to evaluate the interrelationships of structural and
      functional brain damage in this population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Stroke or systemic embolism</measure>
    <time_frame>2018 (after an average of 2.5 years of follow-up)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>2018 (after an average of 2.5 years of follow-up)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial Fibrillation</arm_group_label>
    <description>Cohort Study on patients with atrial fibrillation in Switzerland</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  atrial fibrillation documented within the last 24 months

          -  age &gt;=65 years

        Exclusion Criteria:

          -  acute illness

          -  inability to provide informed consent

          -  Only short episodes of reversible forms of atrial fibrillation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Conen, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Conen, MD MPH</last_name>
    <email>david.conen@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Conen, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>dementia</keyword>
  <keyword>cognitive dysfunction</keyword>
  <keyword>stroke</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
